INS and obesity due to melanocortin 4 receptor deficiency: AhR antagonists should be explored as a potential therapeutic strategy in diabetes due to their ability to reduce inflammation, improve insulin sensitivity, and mitigate obesity-associated metabolic dysfunction [131,247,248].